Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Research Article

埃及患者血清可溶性程序性死亡配体1作为肝细胞癌预后因素的研究

卷 19, 期 11, 2019

页: [896 - 905] 页: 10

弟呕挨: 10.2174/1568009619666190718141647

价格: $65

摘要

背景：程序性细胞死亡配体在肿瘤细胞上的表达在抑制抗肿瘤免疫力中起作用，从而导致肿瘤免疫逃避。 目的：在这项研究中，我们评估了程序性死亡配体1（sPD-L1）的可溶形式对埃及肝细胞癌（HCC）患者的预后价值。 方法：这项前瞻性队列研究在2016年11月至2018年11月之间进行，研究对象为85名患者（25例HCC患者，25例具有血管浸润和/或肝外转移的HCC，25例肝硬化患者，10例健康对照者）。在所有受试者中测定sPD-L1的水平，并在肝硬化和HCC的不同组和阶段中进行比较。评估了sPD-L1水平与总生存期（OS）之间的关联。 结果：不同研究组之间的sPD-L1差异有统计学意义。正常sPD-L1的临界值由健康对照队列中确定的高sPD-L1水平定义。它是2.522 ng / ml。在HCC患者中，临界值是7.42 ng / ml（敏感性88％，特异性100％）。在伴有血管浸润或转移的HCC中，临界值是9.62 ng / ml（敏感性88％，特异性88％）。血清sPD-L1或血清胆红素浓度高的患者死亡风险增加。 结论：高sPD-L1水平可能是肝硬化和HCC患者预后不良的预后指标。将来应研究sPD-L1水平对成功的抗PD1 / PD-L1治疗的预测价值。

关键词: 程序性细胞死亡配体1，肝细胞癌，预后，抗肿瘤免疫，肿瘤，转移。

« Previous Next »
图形摘要

[1]
Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55(2), 74-108.
[http://dx.doi.org/10.3322/canjclin.55.2.74] [PMID: 15761078]
[2]
Ferrone, S.; Whiteside, T.L. Tumor microenvironment and immune escape. Surg. Oncol. Clin. N. Am., 2007, 16(4), 755-774. [viii].
[http://dx.doi.org/10.1016/j.soc.2007.08.004] [PMID: 18022543]
[3]
Carter, L.; Fouser, L.A.; Jussif, J.; Fitz, L.; Deng, B.; Wood, C.R.; Collins, M.; Honjo, T.; Freeman, G.J.; Carreno, B.M. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol., 2002, 32(3), 634-643.
[http://dx.doi.org/10.1002/1521-4141(200203)32:3<634:AID-IMMU634>3.0.CO;2-9] [PMID: 11857337]
[4]
Kassel, R.; Cruise, M.W.; Iezzoni, J.C.; Taylor, N.A.; Pruett, T.L.; Hahn, Y.S. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology, 2009, 50(5), 1625-1637.
[http://dx.doi.org/10.1002/hep.23173] [PMID: 19739236]
[5]
Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol., 2008, 26, 677-704.
[http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331] [PMID: 18173375]
[6]
Afreen, S.; Dermime, S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematol. Oncol. Stem Cell Ther., 2014, 7(1), 1-17.
[http://dx.doi.org/10.1016/j.hemonc.2013.09.005] [PMID: 24398144]
[7]
Ceeraz, S.; Nowak, E.C.; Noelle, R.J. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol., 2013, 34(11), 556-563.
[http://dx.doi.org/10.1016/j.it.2013.07.003] [PMID: 23954143]
[8]
Dong, H.; Zhu, G.; Tamada, K.; Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med., 1999, 5(12), 1365-1369.
[http://dx.doi.org/10.1038/70932] [PMID: 10581077]
[9]
Sheppard, K.A.; Fitz, L.J.; Lee, J.M.; Benander, C.; George, J.A.; Wooters, J.; Qiu, Y.; Jussif, J.M.; Carter, L.L.; Wood, C.R.; Chaudhary, D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett., 2004, 574(1-3), 37-41.
[http://dx.doi.org/10.1016/j.febslet.2004.07.083] [PMID: 15358536]
[10]
Ghebeh, H.; Mohammed, S.; Al-Omair, A.; Qattan, A.; Lehe, C.; Al-Qudaihi, G.; Elkum, N.; Alshabanah, M.; Bin Amer, S.; Tulbah, A.; Ajarim, D.; Al-Tweigeri, T.; Dermime, S. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia, 2006, 8(3), 190-198.
[http://dx.doi.org/10.1593/neo.05733] [PMID: 16611412]
[11]
Jacobs, J.F.; Idema, A.J.; Bol, K.F.; Nierkens, S.; Grauer, O.M.; Wesseling, P.; Grotenhuis, J.A.; Hoogerbrugge, P.M.; de Vries, I.J.; Adema, G.J. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-oncol., 2009, 11(4), 394-402.
[http://dx.doi.org/10.1215/15228517-2008-104] [PMID: 19028999]
[12]
Wu, C.; Zhu, Y.; Jiang, J.; Zhao, J.; Zhang, X.G.; Xu, N. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem., 2006, 108(1), 19-24.
[http://dx.doi.org/10.1016/j.acthis.2006.01.003] [PMID: 16530813]
[13]
Iacovelli, R.; Nolè, F.; Verri, E.; Renne, G.; Paglino, C.; Santoni, M.; Cossu Rocca, M.; Giglione, P.; Aurilio, G.; Cullurà, D.; Cascinu, S.; Porta, C. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target. Oncol., 2016, 11(2), 143-148.
[http://dx.doi.org/10.1007/s11523-015-0392-7] [PMID: 26429561]
[14]
Aguiar, P.N., Jr; Santoro, I.L.; Tadokoro, H.; de Lima Lopes, G.; Filardi, B.A.; Oliveira, P.; Mountzios, G.; de Mello, R.A. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: A network meta-analysis. Immunotherapy, 2016, 8(4), 479-488.
[http://dx.doi.org/10.2217/imt-2015-0002] [PMID: 26973128]
[15]
Yanaba, K.; Hayashi, M.; Yoshihara, Y.; Nakagawa, H. Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis. J. Dermatol., 2016, 43(8), 954-957.
[http://dx.doi.org/10.1111/1346-8138.13339] [PMID: 26945563]
[16]
Shi, B.; Du, X.; Wang, Q.; Chen, Y.; Zhang, X. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases. Metabolism, 2013, 62(6), 778-785.
[http://dx.doi.org/10.1016/j.metabol.2012.12.005] [PMID: 23398844]
[17]
Abd-Elsalam, S.; Elwan, N.; Soliman, H.; Ziada, D.; Elkhalawany, W.; Salama, M.; Hawash, N.; Arafa, M.; Badawi, R.; Shehata, W.M.; Khalil, H.S.; Elmashad, N. Epidemiology of liver cancer in Nile delta over a decade: A single-center study. South Asian J. Cancer, 2018, 7(1), 24-26.
[PMID: 29600229]
[18]
Ziada, D.H.; El Sadany, S.; Soliman, H.; Abd-Elsalam, S.; Salama, M.; Hawash, N.; Selim, A.; Hamisa, M.; Elsabagh, H.M. Prevalence of hepatocellular carcinoma in chronic hepatitis C patients in Mid Delta, Egypt: A single center study. J. Egypt. Natl. Canc. Inst., 2016, 28(4), 257-262.
[http://dx.doi.org/10.1016/j.jnci.2016.06.001] [PMID: 27378258]
[19]
Sheta, E.; El-Kalla, F.; El-Gharib, M.; Kobtan, A.; Elhendawy, M.; Abd-Elsalam, S.; Mansour, L.; Amer, I. Comparison of single-session transarterial chemoembolization combined with microwave ablation or radiofrequency ablation in the treatment of hepatocellular carcinoma: A randomized-controlled study. Eur. J. Gastroenterol. Hepatol., 2016, 28(10), 1198-1203.
[http://dx.doi.org/10.1097/MEG.0000000000000688] [PMID: 27362551]
[20]
Negm, O.; Abou Saif, S.; El Gharib, M.; Yousef, M.; Abd-Elsalam, S. Role of low-molecular-weight heparins in prevention of thromboembolic complication after transarterial chemoembolization in hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 2017, 29(3), 317-321.
[http://dx.doi.org/10.1097/MEG.0000000000000790] [PMID: 27893491]
[21]
Elwan, N.; Salem, M.L.; Kobtan, A.; El-Kalla, F.; Mansour, L.; Yousef, M.; Al-Sabbagh, A.; Zidan, A.A.; Abd-Elsalam, S. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients. Immunol. Invest., 2018, 47(2), 169-180.
[http://dx.doi.org/10.1080/08820139.2017.1407787] [PMID: 29182438]
[22]
Abdelfattah, A.A.M.; Rizk, F.; Hawash, N.; Hanafy, A.; El-Kalla, F.; Abd-Elsalam, S. Randomized trial of preoperative administration of oral pregabalin for postoperative analgesia in patients scheduled for radiofrequency ablation of focal lesions in the liver. Int. J. Hyperthermia, 2018, 34(8), 1367-1371.
[http://dx.doi.org/10.1080/02656736.2018.1424946] [PMID: 29308685]
[23]
Watany, M.; Badawi, R.; Elkhalawany, W.; Abd-Elsalam, S. Abd- Elsalam S. Study of Dickkopf-1 (DKK-1) gene expression in hepatocellular carcinoma patients. J. Clin. Diagn. Res., 2017, 11(2), OC32-OC34.
[PMID: 28384913]
[24]
Huo, T.I. ALBI grade as a new player in hepatocellular carcinoma. J. Chin. Med. Assoc., 2019, 82(1), 1.
[http://dx.doi.org/10.1016/j.jcma.2018.07.001] [PMID: 30839395]
[25]
Gabrielson, A.; Wu, Y.; Wang, H.; Jiang, J.; Kallakury, B.; Gatalica, Z.; Reddy, S.; Kleiner, D.; Fishbein, T.; Johnson, L.; Island, E.; Satoskar, R.; Banovac, F.; Jha, R.; Kachhela, J.; Feng, P.; Zhang, T.; Tesfaye, A.; Prins, P.; Loffredo, C.; Marshall, J.; Weiner, L.; Atkins, M.; He, A.R. Intratumoral CD3 and CD8 T-cell densities associated with relapse free survival in HCC. Cancer Immunol. Res., 2016, 4(5), 419-430.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0110] [PMID: 26968206]
[26]
Ni, W.; Zhang, S.; Jiang, B.; Ni, R.; Xiao, M.; Lu, C.; Liu, J.; Qu, L.; Ni, H.; Zhang, W.; Zhou, P. Identification of cancer-related gene network in hepatocellular carcinoma by combined bioinformatic approach and experimental validation. Pathol. Res. Pract., 2019, 215(6)152428 Epub ahead of print
[http://dx.doi.org/10.1016/j.prp.2019.04.020] [PMID: 31064721]
[27]
European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 2012, 56(4), 908-943.
[http://dx.doi.org/10.1016/j.jhep.2011.12.001] [PMID: 22424438]
[28]
Child, C.G.; Turcotte, J.G. Surgery and portal hypertension. Major Probl. Clin. Surg., 1964, 1, 1-85.
[PMID: 4950264]
[29]
Kamath, P.S.; Wiesner, R.H.; Malinchoc, M.; Kremers, W.; Therneau, T.M.; Kosberg, C.L.; D’Amico, G.; Dickson, E.R.; Kim, W.R. A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33(2), 464-470.
[http://dx.doi.org/10.1053/jhep.2001.22172] [PMID: 11172350]
[30]
Johnson, P.J.; Berhane, S.; Kagebayashi, C.; Satomura, S.; Teng, M.; Reeves, H.L.; O’Beirne, J.; Fox, R.; Skowronska, A.; Palmer, D.; Yeo, W.; Mo, F.; Lai, P.; Iñarrairaegui, M.; Chan, S.L.; Sangro, B.; Miksad, R.; Tada, T.; Kumada, T.; Toyoda, H. Assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach-the ALBI grade. J. Clin. Oncol., 2015, 33(6), 550-558.
[http://dx.doi.org/10.1200/JCO.2014.57.9151] [PMID: 25512453]
[31]
Llovet, J.M.; Brú, C.; Bruix, J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis., 1999, 19(3), 329-338.
[http://dx.doi.org/10.1055/s-2007-1007122] [PMID: 10518312]
[32]
Hanley, J.A.; McNeil, B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 1982, 143(1), 29-36.
[http://dx.doi.org/10.1148/radiology.143.1.7063747] [PMID: 7063747]
[33]
Esmat, G.; El Kassas, M.; Elbaz, T. Hepatocellular carcinoma in Egypt: An updated status, worldwide digestive health day (WDHD); Liver Cancer Act Today, 2013.
[34]
Aravalli, R.N. Development of micro RNA therapeutics for hepatocellular carcinoma. Diagnostics (Basel), 2013, 3(1), 170-191.
[http://dx.doi.org/10.3390/diagnostics3010170] [PMID: 26835673]
[35]
Lee, S.K.; Song, M.J.; Kim, S.H.; Park, M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One, 2019, 14(5)e0216173
[http://dx.doi.org/10.1371/journal.pone.0216173] [PMID: 31048923]
[36]
Hiraoka, A.; Kumada, T.; Tsuji, K.; Takaguchi, K.; Itobayashi, E.; Kariyama, K.; Ochi, H.; Tajiri, K.; Hirooka, M.; Shimada, N.; Ishikawa, T.; Tachi, Y.; Tada, T.; Toyoda, H.; Nouso, K.; Joko, K.; Hiasa, Y.; Michitaka, K.; Kudo, M. Validation of modified ALBI grade for more detailed assessment of hepatic function in hepatocellular carcinoma patients: A multicenter analysis. Liver Cancer, 2019, 8(2), 121-129.
[http://dx.doi.org/10.1159/000488778] [PMID: 31019902]
[37]
Shimose, S.; Tanaka, M.; Iwamoto, H.; Niizeki, T.; Shirono, T.; Aino, H.; Noda, Y.; Kamachi, N.; Okamura, S.; Nakano, M.; Kuromatsu, R.; Kawaguchi, T.; Kawaguchi, A.; Koga, H.; Yokokura, Y.; Torimura, T. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol. Res., 2019. Epub ahead of print
[http://dx.doi.org/10.1111/hepr.13348] [PMID: 30969006]
[38]
Pardoll, D.; Drake, C. Immunotherapy earns its spot in the ranks of cancer therapy. J. Exp. Med., 2012, 209(2), 201-209.
[http://dx.doi.org/10.1084/jem.20112275] [PMID: 22330682]
[39]
Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med., 2015, 372(26), 2521-2532.
[http://dx.doi.org/10.1056/NEJMoa1503093] [PMID: 25891173]
[40]
Garon, E.B.; Rizvi, N.A.; Hui, R.; Leighl, N.; Balmanoukian, A.S.; Eder, J.P.; Patnaik, A.; Aggarwal, C.; Gubens, M.; Horn, L.; Carcereny, E.; Ahn, M.J.; Felip, E.; Lee, J.S.; Hellmann, M.D.; Hamid, O.; Goldman, J.W.; Soria, J.C.; Dolled-Filhart, M.; Rutledge, R.Z.; Zhang, J.; Lunceford, J.K.; Rangwala, R.; Lubiniecki, G.M.; Roach, C.; Emancipator, K.; Gandhi, L. KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med., 2015, 372(21), 2018-2028.
[http://dx.doi.org/10.1056/NEJMoa1501824] [PMID: 25891174]
[41]
El-Khoueiry, A.; Melero, I.; Crocenzi, T.S.; Welling, T.H.; Yau, T.C.; Chopra, W.Y.; Grosso, J.; Lang, L.; Anderson, J.; Cruz, C.M.D.; Sangro, B. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209e040. American Society of Clinical Oncology (ASCO Annual Meeting, 2015.Chicago
[42]
Kew, M. Hepatic tumors and cysts.Gastrointestinal and liver disease; (6th ed. ). , 2002. 2007-2020.
[43]
Lok, A.S.; Sterling, R.K.; Everhart, J.E.; Wright, E.C.; Hoefs, J.C.; Di Bisceglie, A.M.; Morgan, T.R.; Kim, H.Y.; Lee, W.M.; Bonkovsky, H.L.; Dienstag, J.L. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology, 2010, 138(2), 493-502.
[http://dx.doi.org/10.1053/j.gastro.2009.10.031] [PMID: 19852963]
[44]
Kim, H.J.; Park, S.; Kim, K.J.; Seong, J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother. Oncol., 2018, 129(1), 130-135.
[http://dx.doi.org/10.1016/j.radonc.2017.11.027] [PMID: 29366520]
[45]
Finkelmeier, F.; Canli, Ö.; Tal, A.; Pleli, T.; Trojan, J.; Schmidt, M.; Kronenberger, B.; Zeuzem, S.; Piiper, A.; Greten, F.R.; Waidmann, O. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur. J. Cancer, 2016, 59, 152-159.
[http://dx.doi.org/10.1016/j.ejca.2016.03.002] [PMID: 27039170]
[46]
Yamagiwa, S.; Ishikawa, T.; Waguri, N.; Sugitani, S.; Kamimura, K.; Tsuchiya, A.; Takamura, M.; Kawai, H.; Terai, S. Terai1, S. Increase of soluble programmed cell death ligand 1 in patients with Chronic Hepatitis C. Int. J. Med. Sci., 2017, 14(5), 403-411.
[http://dx.doi.org/10.7150/ijms.18784] [PMID: 28539815]
[47]
Gu, X.; Gao, X.S.; Xiong, W.; Guo, W.; Han, L.; Bai, Y.; Peng, C.; Cui, M.; Xie, M. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. OncoTargets Ther., 2016, 9, 4805-4813.
[http://dx.doi.org/10.2147/OTT.S110713] [PMID: 27536144]
[48]
Rossille, D.; Gressier, M.; Damotte, D.; Maucort-Boulch, D.; Pangault, C.; Semana, G.; Le Gouill, S.; Haioun, C.; Tarte, K.; Lamy, T.; Milpied, N.; Fest, T. Groupe Ouest-Est des Leucémies et Autres Maladies du Sang; Groupe Ouest-Est des Leucémies et Autres Maladies du Sang. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: Results from a French multicenter clinical trial. Leukemia, 2014, 28(12), 2367-2375.
[http://dx.doi.org/10.1038/leu.2014.137] [PMID: 24732592]

Rights & Permissions Print Cite
Article Metrics
46
© 2024 Bentham Science Publishers | Privacy Policy